Phone: 1.510.856.5600|info@anthera.com

Press Releases

 
Press Releases
  Date Title and Summary View
Sep 8, 2016
HAYWARD, Calif., Sept. 08, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that it has agreed to sell preferred convertible stock in two tranches to Biotechnology Value Fund, L.P. and other affiliates of BVF Partners L.P. ("BVF"), and Rock Springs Capital for initial proceeds of $17.0 million with an option fo...
Aug 16, 2016
HAYWARD, Calif., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced the appointment of William Shanahan, M.D., J.D. as Chief Medical Officer.  In his role as Chief Medical Officer, Dr. Shanahan will bring his experience as a Rheumatologist and in drug development to lead the blisibimod lupus program and ...
Aug 16, 2016
HAYWARD, Calif., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced that the Data and Safety Monitoring Board (DSMB) completed its first pre-planned safety review of the Phase 3 SOLUTION clinical study of Sollpura™ in cystic fibrosis patients with exocrine pancreatic insufficiency. The DSMB had "no...
Aug 9, 2016
Met enrollment target in SOLUTION study and enrolled first patient in SIMPLICITY study of Sollpura™Successful sachet manufacturing to support SIMPLICITY study and commercial-scale lipase demonstration batchFirst patient enrolled in pivotal CHABLIS 7.5 clinical study of blisibimodPositive trends from analysis of BRIGHT-SC Phase 2 clinical stud...
Aug 3, 2016
HAYWARD, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that the last patient in the Phase 3 CHABLIS-SC1 clinical study, evaluating blisibimod for the treatment of systemic lupus erythematosus, received their final study dose on July 27th.  As described in the protocol, patients are followed ...
Jun 28, 2016
Positive trends from BRIGHT-SC proof-of-concept study - study to continueSOLUTION study with Sollpura completed patient screening ahead of schedule - data in 2016First patients screened in Phase 3 CHABLIS 7.5 study of blisibimod in seropositive lupus patientsCHABLIS-SC1 results to be reported in the third quarter.  Recent DSMB review found no safet...
Jun 15, 2016
May 30, 2016
May 9, 2016
SOLUTION clinical study of Sollpura™ expanded to Europe, Israel and Canada in addition to ongoing US enrollmentCraig Thompson named as President and Chief Operating OfficerAppointment of Dr. James Pennington to Interim Chief Medical OfficerEnrollment of BRIGHT-SC Phase 2 clinical study in IgA Nephropathy completedBulk manufacturing campaign f...
Apr 27, 2016
HAYWARD, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced the appointment of Brent Furse to its Board of Directors. Mr. Furse has over 25 years of healthcare commercial leadership experience with extensive experience in the areas of sales and marketing, commercial product launch and partn...
Page:
1
... NextLast
= add release to Briefcase
Print Friendly